Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?

Area of Science:

• Endocrinology
• Metabolism
• Gerontology

Background:

• Obesity treatment often prioritizes weight loss, raising concerns about preserving fat-free mass (FFM) and skeletal muscle mass (SM).
• Pharmacological interventions, particularly glucagon-like peptide-1 receptor analogs (GLP-1 RA), are increasingly used for obesity management.
• Understanding the impact of these medications on body composition and sarcopenia risk is critical.

Purpose of the Study:

• To review the effects of antiobesity medications, especially GLP-1 RAs, on body composition.
• To assess the risk of sarcopenia associated with GLP-1 RA therapy.
• To identify strategies for preserving muscle mass during pharmacological weight loss.

Main Methods:

• Literature review of studies investigating GLP-1 RAs and body composition.
• Analysis of research on sarcopenia risk factors in the context of weight loss medications.
• Evaluation of interventions aimed at preserving muscle mass.

Main Results:

• GLP-1 RAs effectively reduce fat mass, but up to 40% of weight loss may stem from FFM.
• Distinguishing between FFM and SM is important, as FFM includes non-muscle components.
• Resistance training and protein intake show mixed efficacy; nutrients (e.g., BCAAs, creatine) and novel agents (e.g., bimagrumab) may help preserve muscle mass.

Conclusions:

• GLP-1 RA therapy for obesity necessitates concurrent strategies to preserve muscle mass, including resistance training and optimal protein intake.
• Nutritional supplements and emerging pharmacological agents show promise in mitigating muscle loss.
• Further research is required to understand long-term effects on muscle health and optimize sarcopenia prevention.